Article Details

Takeda keeps divestment spree rolling with $1.2B sale of diabetes meds to Japanese firm Teijin

Retrieved on: 2021-03-02 15:33:45

Tags for this article:

Click the tags to see associated articles and topics

Takeda keeps divestment spree rolling with $1.2B sale of diabetes meds to Japanese firm Teijin. View article details on hiswai:

Excerpt

... freeing up the company to focus on its core businesses in gastroenterology, rare diseases, plasma-derived therapies, oncology and neuroscience.

Article found on: www.fiercepharma.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo